Alpelisib Nearly Doubles PFS in PIK3-Mutated Breast Cancer Alpelisib Nearly Doubles PFS in PIK3-Mutated Breast Cancer

A novel PIK3 inhibitor combined with fulvestrant nearly doubled progression- free survival (PFS) in PIK3CA-mutated breast cancer.Medscape Medical News

Source: Medscape Medical News Headlines - May 15, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news